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rythropoiesis requires tight control of expansion, matu-
ration, and survival of erythroid progenitors. Because
activation of phosphatidylinositol-3-kinase (PI3K) is
required for erythropoietin/stem cell factor–induced expan-
sion of erythroid progenitors, we examined the role of the
PI3K-controlled Forkhead box, class O (FoxO) subfamily of
Forkhead transcription factors. FoxO3a expression and
nuclear accumulation increased during erythroid differ-
entiation, whereas untimely induction of FoxO3a activ-
ity accelerated differentiation of erythroid progenitors to
erythrocytes. We identiﬁed 
 
B cell translocation gene 1
 
(
 
BTG1
 
)
 
/antiproliferative protein 2 
 
as a FoxO3a target gene
E
 
in erythroid progenitors. Promoter studies indicated 
 
BTG1
 
as a direct target of FoxO3a. Expression of BTG1 in primary
mouse bone marrow cells blocked the outgrowth of eryth-
roid colonies, which required a domain of BTG1 that binds
protein arginine methyl transferase 1. During erythroid differ-
entiation, increased arginine methylation coincided with
BTG1 expression. Concordantly, inhibition of methyl trans-
ferase activity blocked erythroid maturation without affecting
expansion of progenitor cells. We propose FoxO3a-controlled
expression of
 
 
 
BTG1 and subsequent regulation of protein
arginine methyl transferase activity as a novel mechanism
controlling erythroid expansion and differentiation.
 
Introduction
 
Homeostasis of the hematopoietic system requires tight control
of expansion, differentiation, and survival of progenitor
cells, which is exerted by numerous cytokines and growth
factors acting on specific cell types, such as erythropoietin
(Epo), or on multiple types of progenitors, such as stem cell
factor (SCF). The role of SCF in hematopoiesis is mainly to
stimulate expansion and delay differentiation of hematopoietic
progenitors in cooperation with more cell type–specific
factors (for review see Broudy, 1997).
Erythroid progenitors can be expanded in the presence of
Epo, SCF, and dexamethasone (Dex); whereas they differen-
tiate into enucleated, hemoglobinized erythrocytes in the
presence of Epo alone (Dolznig et al., 2001; von Lindern et
al., 2001). Differentiation involves four differentiation-specific
cell divisions with altered cell cycle regulation until a terminal
G1 arrest is reached. SCF considerably delays differentiation,
eventually yielding 
 
 
 
20-fold increased numbers of mature
erythrocytes. Erythroid differentiation is thought to be an
autonomously regulated cascade of events in which Epo
signaling is mainly required for survival and constitutive
BCL-X
 
L
 
 expression is sufficient to allow erythroid differenti-
ation in defined medium lacking any factors (Dolznig et al.,
2002). SCF, a potent activator of phosphatidylinositol-3-
kinase 
 
(
 
PI3K) in erythroid progenitors, is unable to induce
cell survival in the absence of Epo (Dolznig et al., 2001; von
Lindern et al., 2001). Instead, SCF signaling is required to
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delay differentiation, which is abrogated by PI3K inhibitor
LY294002 (von Lindern et al., 2001). Both Epo and SCF
activate PI3K and its target PKB (c-AKT; Bao et al., 1999).
However, compared with Epo, SCF is much more potent in
inducing PKB phosphorylation (von Lindern et al., 2001).
Phosphorylation and activation of the serine/threonine ki-
nase PKB controls fundamental processes such as cell cycle
progression, apoptosis, and mRNA translation (Datta et al.,
1999; Raught and Gingras, 1999; Brazil and Hemmings,
2001). The Forkhead box, class O (FoxO) subfamily of
Forkhead transcription factors is an important effector
of PKB in regulating apoptosis and cell cycle progres-
sion. Members of this subfamily, FoxO4 (AFX), FoxO1a
(FKHR), and FoxO3a (FKHR-L1), are directly phosphory-
lated by PKB, leading to cytoplasmic retention and inhibi-
tion of their transcriptional activity (Brunet et al., 1999;
Kops et al., 1999; Tang et al., 1999). In the absence of phos-
phorylation, these transcription factors induce expression of
genes encoding proteins that inhibit the cell cycle like p27
 
Kip
 
(Dijkers et al., 2000b; Medema et al., 2000), p130-Rb2
(Kops et al., 2002), and cyclin G2 (Ramaswamy et al.,
2002), or proapoptotic proteins like Bim (Dijkers et al.,
2000a) and the transcriptional repressor BCL-6, which in-
hibits expression of the antiapoptotic factor BCL-X
 
L
 
 (Tang
et al., 2002). Whether FoxO activation results in cell cycle
arrest, induction of apoptosis, or other cell fates will depend
on the cellular context.
We investigated the potential role of FoxO family mem-
bers during expansion and differentiation of erythroid pro-
genitors. FoxO3a expression increases during differentia-
tion, resulting in nuclear accumulation 48 h after induction
of differentiation. Activation of a phosphorylation-insensi-
tive FoxO3a mutant accelerated differentiation under condi-
tions favoring renewal. DNA microarray screens identified 
 
B
cell translocation gene 1 (BTG1)/antiproliferative protein 2
 
 as
a novel FoxO3a target. Ectopic expression of BTG1 inhib-
ited the expansion of mouse erythroid progenitor cells,
which was dependent on the protein arginine methyl trans-
ferase 1 (PRMT1)–binding domain of BTG. We present
data that suggest that modulation of protein arginine meth-
ylation activity by BTG1 may present a new FoxO-depen-
dent mechanism regulating erythroid differentiation.
 
Results
 
FoxO3a expression and activity increase during 
erythroid differentiation
 
In search of PI3K-dependent pathways involved in the main-
tenance of erythroid progenitor renewal, we analyzed expres-
sion and function of the PI3K/PKB-regulated Forkhead fam-
ily members FoxO4, FoxO1a, and FoxO3a during expansion
and differentiation of the p53-deficient I/11 erythroid cell
line. After induction of differentiation, expression of FoxO1a
and FoxO4 increased for 24 h, but then rapidly declined to
levels lower than those observed under renewal conditions
(Fig. 1 A). In contrast, FoxO3a expression sharply increased
12–24 h after differentiation induction (Fig. 1 B), reaching
maximal expression at 48 h and remaining high until com-
pletion of differentiation at 72 h (Fig. 1, A and B). Essentially
the same results were obtained with primary erythroid pro-
genitors expanded from E12.5 fetal livers, except that these
cells express maximal levels of FoxO3a at 24 h and complete
differentiation in 48 h (unpublished data).
FoxO3a function is regulated by phosphorylation. In fac-
tor-deprived and restimulated erythroblasts, SCF induced a
strong transient phosphorylation of FoxO3a serine residue
253, whereas Epo only weakly induced phosphorylation of
FoxO3a (Fig. 1 C). In Fig. 1 C, the unidentified protein X is
phosphorylated in factor-deprived cells and dephosphory-
lated after Epo or SCF stimulation. Phosphorylation of pro-
tein X is equally strong at time 0 in both panels, the much
more pronounced signal in the Epo stimulation experiment
is due to an accordantly longer exposure of the blot. Upon
induction of differentiation, phosphorylation of FoxO3a
reached maximum levels after 36 h and decreased thereafter,
whereas total FoxO3a expression still increased (Fig. 1 D, the
band detected at 72 h by the phosphospecific antibody may
be the same protein X detected in Fig. 1 C). FoxO3a phos-
phorylation coincided with reduced expression and phos-
phorylation of PKB (Fig. 1 D, third and fourth panels).
Consequently, unphosphorylated FoxO3a- and thus FoxO3a-
mediated transcription increased from 36 h onwards as mon-
itored by expression of the FoxO3a target p27
 
Kip
 
 (Fig. 1 D,
third panel). This is accompanied by increased nuclear local-
ization of FoxO3a (Fig. 1 E; 72 h after induction of differen-
tiation the cells are enucleated, hence no nuclear localization
Figure 1. FoxO3a expression and activ-
ity increases during erythroid differenti-
ation. (A) Western blots of differentiating 
I/11 cells (samples taken every 12 h) were 
analyzed with antibodies recognizing 
FoxO1a, FoxO3a, and FoxO4. ERK 
protein levels do not change during differ-
entiation (loading control). (B) Western 
blot analysis of FoxO3a total protein levels 
during the first 24 h of differentiation 
(ERK expression serves as loading control). 
(C) I/11 cells were factor deprived and 
stimulated with 5 U/ml Epo and 1  g/ml 
SCF for increasing time periods as indi-
cated. Blots were analyzed with phospho-
specific FoxO3a antibodies (S253) and 
antibodies recognizing total FoxO3a. An 
unidentified, cross-hybridizing protein 
(X) is dephosphorylated in response to 
Epo and SCF. Its signal is comparable at 
time 0 in the Epo and SCF panel when 
equally exposed. (D) Western blots of 
differentiating I/11 cells (samples taken 
every 12 h) were analyzed with antibodies 
recognizing FoxO3a and S253-phos-
phorylated FoxO3a, PKB and S473-
phosphorylated PKB, and p27
Kip and 
Erk. The protein recognized by 
phosphoSer253-FOXO3a antibodies at 
72 h is unknown and may be the same 
background band X detected by this anti-
body in C. (E) Cytoplasmic and nuclear 
protein extracts of differentiating I/11 
cells were analyzed with antibodies 
recognizing FoxO3a, STAT3, and ERK. 
Under these conditions, STAT3 is only present in the cytoplasm, in-
dicating minimal contamination of nuclear extracts with cytoplasmic 
proteins. ERK expression serves as a loading control. 
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can be detected). Together, FoxO3a is up-regulated early in
differentiation and is transcriptionally active 
 
 
 
36–48 h after
induction of differentiation, as indicated by its phosphoryla-
tion status and the expression of the target p27
 
Kip
 
.
 
Physiological effects of FoxO3a 
in erythroid differentiation
 
Although FoxO1a, FoxO3a, and FoxO4 may control cell cy-
cle progression and cell survival of renewing cells, the expres-
sion pattern of Foxo3a suggests an additional role in erythroid
differentiation. To investigate the role of FoxO3a, we used an
inducible, phosphorylation-insensitive FoxO3a(A3):estrogen
receptor (ER) fusion construct in which three serine
phosphorylation sites are mutated to alanines. Fusion of this
mutant to an estrogen receptor domain allows induction of
nuclear translocation of FoxO3a(A3):ER by 4-hydroxytamox-
ifen (4OHT; Dijkers et al., 2000a). The FoxO3a(A3):
ER protein was expressed in I/11 erythroid progenitors by
retroviral transduction. Exposure of FoxO3a(A3):ER-express-
ing cells to 50 nM 4OHT induced p27
 
Kip
 
 protein levels in 8
out of 10 clones, which did not occur in empty vector-trans-
duced cells (unpublished data). To test whether activation of
FoxO3a(A3):ER could counteract SCF-induced delay of Epo-
dependent differentiation, FoxO3a(A3):ER clones and empty
vector control clones were cultured in Epo or in Epo plus
SCF, both in the presence or absence of 50 nM 4OHT. Cell
numbers, cell size, hemoglobin levels, and cell morphology
were monitored daily. 4OHT did not affect proliferation
or differentiation of control clones, whereas it slightly de-
creased proliferation and enhanced hemoglobinization of
FoxO3a(A3):ER clones in the presence of Epo (Fig. 2 A). In
the presence of Epo and SCF, proliferation was impeded,
which was accompanied with enhanced differentiation as ana-
lyzed by hemoglobinization (Fig. 2 B) and cell morphology
(Fig. 2 C). 4OHT increased the number of partially mature
and mature hemoglobinized cells, but cytospins showed no
evidence for increased cell death (Fig. 2 C). We did not
observe an increase in apoptotic cells on FoxO3a(A3):ER acti-
vation, using a TUNEL assay (Fig. 2 D). This observation in-
dicated that exogenous, active FoxO3a accelerates differentia-
tion of erythroid progenitors. Also, in the presence of Epo,
SCF, and Dex, activation of FoxO3a(A3):ER abrogated re-
Figure 2. FoxO3a induces erythroid differentiation. 
All FoxO3a(A3):ER clones used had similar expression 
levels of the mutant FoxO3a protein, and treatment of 
all clones induced rapid up-regulation of p27
Kip (not 
depicted). (A and B) A vector-transduced clone (EV1) 
and FoxO3a(A3):ER-expressing clones F5 and F6 were 
seeded in differentiation medium containing Epo (A) 
or Epo plus SCF (B), in the absence (open diamonds) or 
presence (closed squares) of 50 nM 4OHT. Cumulative 
cell numbers (top) and hemoglobin content per cell 
volume (bottom) were determined at daily intervals. 
(C) At day 4 of the experiments, cell morphology and 
hemoglobin content was analyzed in cytospins. Hemo-
globinized cells can be discriminated by their orange-
brown staining. (D) The vector control clone (EV1) and 
two FoxO3a(A3):ER clones (F10 and F12) were cultured 
in the presence of Epo, SCF, and Dex in the presence 
or absence of 4OHT. As a control, parental I/11 cells 
were seeded in medium lacking factors. After 24 h, the 
percentage of apoptotic cells was determined by a 
TUNEL assay. Values represent mean   SD of apoptotic 
cells counted in five fields of a cytospin preparation 
(100 cells/field) in two independent experiments. (E) 
Phoenix E cells were transfected with FoxO3a wild type 
alone or in combination with RNAi constructs FOXi1–4 
(see Materials and methods). Transient expression of 
FoxO3a was determined by Western blot (Erk serves 
as a loading control). (F) I/11 clones, transduced with 
pSuper-retro vector as a control (ev1 and ev2) or pSuper-
retro FOXi2 (clone numbers indicated) were tested for 
FoxO3a on Western blot. (G) Two empty vector (ev1 
and ev2) and four FOXi2 clones (clone numbers indi-
cated) were differentiated in the presence of Epo. The 
hemoglobin content of the cells was measured at 0, 48, 
and 72 h in differentiation. Values represent mean   SD 
of three experiments. 
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custom-made “hematopoietic” DNA microarrays containing
 
 
 
9,000 cDNAs derived from SSH libraries enriched for
transcripts of expanding erythroblasts (I/11 cells) and ma-
ture T cells (Kolbus et al., 2003). These microarrays con-
tained multiple copies of abundant erythroid-specific cDNAs
(up to a few hundred for 
 
 
 
-globin). The complete array re-
sults are available as supplemental data (Table S1, available
at http://www.jcb.org/cgi/content/full/jcb.200307056/DC1).
Upon 4OHT treatment of FoxO3a(A3):ER-expressing cells
for 2 h, seven transcripts in the array were up-regulated
 
 
 
1.75-fold compared with no treatment, whereas no up-
regulated genes were detected in similarly treated control
cells. Five out of those seven transcripts represented 
 
BTG1
 
,
with an average up-regulation of 1.9 
 
 
 
 0.14 (Fig. 3 A).
Upon 6 h of 4OHT treatment, 98 transcripts indicated a
 
 
 
1.75-fold increase compared with no treatment. 11 of
these represented 
 
BTG1
 
. Their average fold up-regulation
was 2.9 
 
 
 
 0.33 (Fig. 3, A and B). None of these transcripts
was detected in the control experiment.
The same arrays were also screened for genes up- or down-
regulated in I/11 cells that were factor depleted and subse-
quently restimulated with Epo and/or SCF (Kolbus et al.,
2003). Among the FoxO3a targets up-regulated after 6 h,
only the transcripts representing 
 
BTG1
 
 were down-regulated
by Epo and SCF signaling as expected for genes primarily
regulated by FoxO3a (Fig. 3 C and not depicted). There-
fore, we concentrated on 
 
BTG1
 
 as a novel putative FoxO3a
target. Two additional FoxO3a(A3):ER clones were treated
for 2 h with 50 nM 4OHT, and 
 
BTG1
 
 transcript levels were
determined by real-time PCR. In both clones, 
 
BTG1
 
 ex-
pression was twofold up-regulated, whereas control clones
showed no change in 
 
BTG1
 
 expression (Fig. 3 D). Cyclo-
hexamide treatment of I/11 cells strongly up-regulated
 
BTG1
 
, which precluded its use to determine whether pro-
tein synthesis is required for 
 
BTG1
 
 up-regulation.
Together, we identified 
 
BTG1
 
 as a prominent FoxO3a tar-
get in this screen. We also show that mitogenic signaling sup-
presses 
 
BTG1
 
 expression, which is in accordance with the ob-
served Epo- and SCF-induced phosphorylation of FoxO3a.
 
BTG1
 
 is a direct FoxO3a target
 
To examine whether 
 
BTG1
 
 is a direct target of FoxO3a, we
analyzed the 
 
BTG1
 
 promoter region for putative FoxO-
binding sites. Among the sequences submitted to the public
database, mouse cDNA clone L16846 contained the longest
5
 
 
 
UTR sequence. A comparison with genomic sequences in
the CELERA database showed that the start of cDNA
L16846 (designated 
 
 
 
1) is located 40 nt downstream of a
conserved TATA-box sequence (Fig. 4 A). We found four
potential Forkhead-binding sites (Daf-16 binding element
[DBE]) at position 
 
 
 
219, 
 
 
 
454, 
 
 
 
826, and 
 
 
 
922 (Fig. 4
B), allowing a 1-bp mismatch compared with the consensus
sequence TTGTTTAC (Furuyama et al., 2000) outside the
TGTT core sequence. Only DBE1 (position 
 
 
 
219) com-
pletely matched the consensus sequence, and an alignment
between the mouse and human 
 
BTG1
 
 promoter sequence
(BAC AC025164) revealed that only DBE1 was 100% iden-
tical between mouse and human (Fig. 4 A).
To determine which part of the 
 
BTG1
 
 promoter mediates
FoxO3a-induced expression, genomic fragments containing
Figure 3. BTG1, a FoxO3a target gene. Labeled cDNA from 
FoxO3a(A3):ER clone F14 and vector clone EV1, exposed to 50 nM 
4OHT for 0, 2, and 6 h in the presence of Epo, SCF, and Dex, were 
hybridized to a 9,000 cDNA microarray enriched for hematopoietic 
transcripts. (A) The number of spots that detected a  1.75-fold increase 
in signal upon treatment with 4OHT compared with nontreated cells 
is indicated for both clones after 2 and 6 h of treatment. BTG1 was 
represented at least 11 times on these arrays, 5 of these BTG1 spots 
showed  1.75-fold up-regulation after 2-h induction with 4OHT. 
(B and C) The average regulation on the 11 BTG1 spots is calculated 
after 2 and 6 h of 4OHT treatment (B) and after 2 h of Epo, SCF, or 
Epo plus SCF induction of factor-deprived cells (C), 1 meaning no 
regulation. Error bars indicate SD. (D) Control clone EV1 and 
FoxO3a(A3):ER clones F10 and F15 were treated with 50 nM 4OHT 
for 2 h, and relative BTG1 expression was determined by real-time 
PCR, using expression of RNase inhibitor to normalize the values. 
Values represent mean   SD of three independent experiments.
 
newal and induced differentiation. However, the presence of
Dex interferes with hemoglobin synthesis and precludes the
use of this parameter to monitor differentiation accurately.
Using siRNA, we examined whether underexpression of
FoxO3a impaired or delayed erythroid differentiation. An
siRNA that fully blocked FoxO3a in a transient assay (Fig.
2 E, FOXi2) resulted in a considerable, but not complete, re-
duction of FoxO3a expression upon stable expression in
erythroid progenitors (Fig. 2 F). After induction of differenti-
ation, reduced FoxO3a expression attenuated differentiation
as measured by hemoglobinization (Fig. 2 G). Thus, activa-
tion of FoxO3a accelerated differentiation, and reduced levels
of Fox3a suppress maturation during differentiation.
 
FoxO3a target genes in erythroid cells
 
Although the FoxO3a target p27
 
Kip
 
 can induce cell cycle ar-
rest and differentiation in some cell types, overexpression of
p27
 
Kip
 
 induced apoptosis in erythroblasts, whereas erythroid
differentiation was normal in p27
 
Kip
 
-deficient cells (Hof-
mann et al., 2001; unpublished data). In addition to known
targets that cause apoptosis or cell cycle arrest, FoxO3a
could induce unknown targets that function in erythroid
differentiation. To identify such target genes, cDNA derived
from a FoxO3a(A3):ER-expressing clone and a control clone
exposed to 50 nM 4OHT for 0, 2, or 6 h were hybridized to 
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all four DBEs (
 
 
 
1033/
 
 
 
82), DBE1 (
 
 
 
314/
 
 
 
82), or no
DBE sites (
 
 
 
67/
 
 
 
82) were tested for basal promoter activity
in Ba/F3 (hematopoietic, pro-B cells), COS (monkey kidney
cells), and NIH3T3 (fibroblasts; Fig. 4, B and C). The activ-
ity of the different reporter constructs was similar in all cell
types. The promoter activity of the 
 
 
 
1033/
 
 
 
82 and the
 
 
 
314/
 
 
 
82 fragments was equally high, whereas the pro-
moter activity of the 
 
 
 
67/
 
 
 
82 
 
BTG1
 
 promoter fragment
was almost reduced to background levels, indicating the pres-
ence of a crucial regulatory element between 
 
 
 
314 and 
 
 
 
67.
To investigate the role of DBE1, the TGTT core was mu-
tated to AAAT in the 
 
 
 
1033/
 
 
 
82 and 
 
 
 
314/
 
 
 
82 con-
structs. This mutation caused a significant loss of basal pro-
moter activity in both fragments (Fig. 4 D), indicating that
DBE1 is a critical element in the 
 
BTG1
 
 promoter. Cotrans-
fection of FoxO3a(A3) with the wild-type and mutant
 
 
 
314/
 
 
 
82 promoter induced wild-type but not mutant
 
 
 
314/
 
 
 
82 
 
BTG1
 
 promoter activity (Fig. 4 E). Together,
these data suggest that FoxO3a is able to activate transcrip-
tion of 
 
BTG1
 
 via the DBE1 element in the 
 
BTG1
 
 promoter.
 
BTG1
 
 is up-regulated in erythroid differentiation
 
If BTG1 is a FoxO3a target, its mRNA expression should
follow FoxO3a activity during differentiation of erythroid
progenitors. We determined BTG1 transcript levels during
erythroid differentiation by Northern blot and real-time
PCR (Fig. 5), using mRNA prepared from I/11 cells har-
vested at 12-h intervals after differentiation induction.
BTG1 mRNA expression was low until 36 h after induction
of differentiation when cells still proliferate. BTG1 tran-
script levels strongly increased 48 h after differentiation in-
duction when cells become postmitotic and remained high
until the final stages of erythroid differentiation (Fig. 5).
Thus, BTG1 is expressed upon appearance of active FoxO3a
during differentiation, suggesting a role of BTG1 in late
erythroid differentiation.
BTG1 may act via protein arginine methylation 
during differentiation
BTG1 is one of six family members, all sharing two highly
homologous domains (BoxA and B; Fig. 6 A). It shares a
third region of homology with BTG2 (BoxC), which associ-
ates with PRMT1 (Lin et al., 1996; Berthet et al., 2002).
Overexpression of the BTG1 BoxC domain has been shown
to inhibit differentiation of PC12 cells (Berthet et al., 2002).
We expressed BTG1 in the I/11 erythroid progenitors, but
only obtained small differentiated clones that could not be
expanded (unpublished data). BTG1:ER fusion constructs as
used for FoxO3a were not regulated tight enough. Because
bone marrow is transduced with much higher efficiencies
than I/11 cells, we transduced murine primary bone marrow
to examine proliferation and differentiation in suspension
cultures and in colony assays, using retroviral expression vec-
tors containing BTG1 wild type or a BTG1 construct lacking
boxC (BTG1- BoxC). Colony formation of transduced cells
was determined in serum-free semisolid medium supple-
mented with granulocyte–macrophage colony-stimulating
factor (GM-CSF; myeloid colonies) or with a combination of
Epo, SCF, and Dex (producing exclusively erythroid colonies
as Dex inhibits outgrowth of SCF-dependent, nonerythroid
Figure 4. Regulation of BTG1 promoter activity by FoxO3a. (A) 
Sequence of the promoter region (plain) and part of the first exon 
(bold italics) of BTG1. Top sequence is derived from the mouse 
CELERA database and cDNA clone L16846, the bottom sequence is 
derived from the human BAC AC025164. The start of mouse cDNA 
L16846 was assigned as position 1. A potential TATA-box and 
FoxO-binding site (DBE1) are indicated. (B) Schematic drawing of 
the BTG1 promoter fragments used in reporter assays. Four potential 
FoxO-binding sites, DBE1–4, were found in the  1033/ 82 promoter 
fragment. (C) Basal BTG1 promoter activity of these fragments was 
tested in COS, NIH3T3, and Ba/F3 cells and compared with a vector 
control (pGL3). Luciferase activity is represented as arbitrary units. 
Values represent mean   SD of three measurements. (D) Both  1033/
 82 and  314/ 82 fragments with either a wild-type or a mutated 
DBE1 were tested for basal promoter activity in COS cells. The 
 67/ 82 fragment serves as a negative control. (E) COS cells were 
cotransfected with FoxO3a(A3) and the  314/ 82 BTG1 promoter 
with either a wild-type or a mutated DBE1. Luciferase activity is 
presented as fold induction on the horizontal axis. Values represent 
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colonies; controlled by cytospins [unpublished data]). Addi-
tion of puromycin selected for the outgrowth of transduced
cells only. Bone marrow was infected with supernatants con-
taining equal numbers of virus as controlled by dot-blot ex-
periments (Erkeland et al., 2003; unpublished data). Colo-
nies were counted 7 d after plating. Ectopic expression of
BTG1 drastically reduced both the size and the number of
erythroid colonies (Fig. 6 B, smallest, average, and largest col-
onies), whereas it only slightly reduced the number of my-
eloid colonies (Fig. 6 C). In contrast, erythroid colonies ex-
pressing BTG1- BoxC were normal in size and only slightly
reduced in number compared with the vector–control colo-
nies (Fig. 6, B and C). Though the total number of colonies
obtained differed between experiments (between 95 and 266
colonies in the vector control), the relative number of colo-
nies obtained upon transduction of the various constructs
was constant. Therefore, colonies are given as a percentage of
control. Essentially the same results were obtained in suspen-
sion cultures (Fig. 6 D). This result indicates that BTG1 ab-
rogates proliferation and that this effect depends on the pres-
ence of the PRMT1 interaction domain in boxC.
Because boxC of BTG1 interacts with PRMT1, we inves-
tigated whether protein arginine methylation is associated
with BTG1 expression. Two different antibodies (7E6, rec-
ognizing mono- and dimethyl-arginine, and ASYM24, rec-
ognizing only asymmetrical dimethyl-arginine) were used to
immunoprecipitate arginine-methylated proteins from ly-
sates of cells at different stages of differentiation. Concurrent
with the activation of FOXO3a and the up-regulation of
BTG1, the 7E6 antibody detected a prominent protein of
100 kD (Fig. 7 A, top panel). The ASYM24 antibody de-
tected proteins of 45, 40, and 37 kD, which appeared after
up-regulation of BTG1 (Fig. 7 A, second panel). ASYM24
also detects abundant proteins that are methylated at all
stages of differentiation. In contrast, the overall PRMT1
protein levels in the same lysates remained constant during
differentiation (Fig. 7 A, bottom panel).
To examine whether inhibition of methylation affects the
balance between expansion and differentiation of erythroid
progenitors, I/11 erythroblasts were seeded in differentia-
tion medium containing Epo or Epo plus SCF to analyze
differentiation. Aliquots were exposed to the methyl-trans-
ferase inhibitor 5 -deoxy-5 -methylthioadenosine (MTA;
10 and 25  M) or its solvent. Cell numbers, cell volume,
hemoglobinization, and cell morphology were monitored
daily. In the presence of Epo, I/11 cells achieve full hemo-
globinization in 3 d, but addition of MTA (both 10 and 25
 M) impairs hemoglobin accumulation (Fig. 7 B). In
cytospins generated at day 3, the control cells are hemoglo-
binized and enucleated, whereas MTA-treated cells main-
tained blast morphology (Fig. 7 C). In the presence of Epo
and SCF, erythroblasts reduced cell size and accumulated
hemoglobin at day 8, whereas they retained blast morphol-
ogy and continued to proliferate in the presence of MTA.
This showed that inhibition of methyl transferases impairs
differentiation but fails to affect proliferation of erythroid
progenitors. Although the inhibitor is not specific for
PRMT1, these results support a potential role of PRMT1
in terminal erythroid differentiation.
Figure 5. BTG1 is transcriptionally up-
regulated during erythroid differentia-
tion. (A) Total RNA was isolated from 
differentiating erythroid progenitors at 12-h 
intervals. BTG1 transcript levels were 
detected using a SmaI–BamHI 211-bp 
fragment as a probe (top). Ethidium bro-
mide staining (bottom) indicated equal 
loading. (B) Real-time PCR on the RNA 
samples confirmed the kinetics in a quan-
titative way, using SYBR green in Taqman 
analysis and normalizing to the expression 
of the RNase inhibitor RI. Values represent 
mean   SD of three measurements.
Figure 6. BTG1 inhibits proliferation of erythroid progenitors. (A) 
Schematic drawing of the 171–amino acid BTG1 protein, indicating 
the conserved domains A–C. (B–D) Density-purified murine bone 
marrow progenitors were transduced with an empty vector and 
retroviral expression vectors encoding BTG1 or BTG1 ( BoxC). Trans-
duced cells were selected with puromycin in serum-free semisolid 
medium supplemented with 2 U/ml Epo, 100 ng/ml SCF, and 10
 6 M 
Dex or with 10 ng/ml GM-CSF. Cytospins showed that all colonies 
grown with Epo, SCF, and Dex contain erythroid cells, whereas GM-
CSF allows colony formation by various myeloid progenitors (not 
depicted). 7 d after plating, the morphology of erythroid colonies was 
photographed with a CCD camera (B, left to right: smallest, average, 
and largest colony) and colonies were counted (C). Values represent 
mean   SD of three independent experiments each counted in triplo. 
Transduced cells were also grown in suspension cultures under 
conditions favoring expansion of erythroid progenitors, and total cell 
numbers were determined daily. An antisense BTG1 construct is 
added as a control (D).FoxO3a controls BTG1 expression in erythroblasts | Bakker et al. 181
Discussion
FoxO3a expression increases sharply during erythroid differ-
entiation, followed by loss of phosphorylation and increased
transcriptional activity. Inappropriate activation of FoxO3a
accelerates differentiation of erythroid progenitors to eryth-
rocytes.  BTG1 was identified as a novel target gene of
FoxO3a, repressed by SCF and exerting a negative effect on
erythroid progenitor renewal. Deletion of BoxC in BTG1, a
domain known to bind PRMT1, abrogated proliferation in-
hibition by BTG1, suggesting that protein arginine methyla-
tion might interfere with renewal. This finding is supported
by the observation that inhibition of methyl transferase ac-
tivity does not interfere with progenitor expansion, but
blocks differentiation into mature erythrocytes.
PI3K and FoxO3a control the balance between 
renewal divisions and differentiation of 
erythroid progenitors
PI3K-dependent signaling is associated with expansion of
erythroid progenitors (Klingmuller et al., 1997; Haseyama et
al., 1999; von Lindern et al., 2001). Both Epo and SCF pro-
mote erythroid proliferation by inhibition of FoxOs, whereas
active FoxO3a was shown to cause cell cycle arrest and apop-
tosis in erythroblasts unless inhibited by phosphorylation
through PKB (Kashii et al., 2000; Mahmud et al., 2002). We
find FoxO1a, FoxO3a, and FoxO4 to be expressed in renew-
ing erythroid progenitors. The disappearance of FoxO1a and
FoxO4 in differentiation suggests that these FoxO members
may specifically have a role in the PI3K-dependent control of
progenitor expansion, possibly via previously reported effector
pathways (Dijkers et al., 2000a,b; Medema et al., 2000; Kops
et al., 2002; Ramaswamy et al., 2002). Actually, the three
FoxO members may have overlapping functions in the con-
trol of progenitor expansion. However, because not only acti-
vation of FoxO3a but also inhibition of PI3K activity induced
differentiation rather than apoptosis, all three FoxO members
may be able to abrogate renewal and initiate the differentia-
tion program. Once the differentiation program is started,
only FoxO3a is up-regulated and only FoxO3a may control
gene expression in late differentiation, including BTG1. Al-
though activation of FoxO3a enhanced differentiation, RNA
interference (RNAi) suppressing FoxO3a impaired differenti-
ation as monitored by reduced hemoglobinization. However,
inhibition of FoxO3a did not abrogate differentiation. Possi-
bly, the remaining expression of FoxO3a is sufficient to allow
the differentiation process to proceed. Alternatively, the tight
control of erythroid cell numbers, evidenced by the very rare
occurrence of erythroid leukemia, has recruited several com-
plementary mechanisms that guarantee proper differentiation
of erythroid progenitors. The observation that FoxO3a-defi-
cient mice develop a compensated anemia with reticulocytosis
(Castrillon et al., 2003) illustrates the importance of FoxO3a
in erythroid differentiation. The reticulocytosis suggests that
the anemia is caused by instability of erythrocytes rather than
by increased apoptosis of progenitors.
The role of FoxO3a in erythroid differentiation
After induction of differentiation, erythroid progenitors un-
dergo three to four cell divisions while maturing to hemoglo-
binized, enucleated erythrocytes (Dolznig et al., 2001; von
Lindern et al., 2001). Activated FoxO3a induced expression
of p27
Kip and p130-Rb2 in erythroblasts as has been shown
for other cell types (confirmed by quantitative PCR [unpub-
lished data]; Dijkers et al., 2000b; Medema et al., 2000; Kops
et al., 2002). Forced activation of FoxO3a accelerated differ-
entiation and reduced the number of cell divisions. FoxO3a-
induced expression of p27
KIP and p130-Rb2 most likely con-
tributed to G1 arrest. However, cell cycle arrest caused by
exogenous p27
Kip fails to induce terminal differentiation of
erythroid progenitors, causing apoptosis instead (Hofmann et
al., 2001). Furthermore, erythroid progenitors lacking p27
Kip
Figure 7. Protein methylation is associated with differentiation but 
not with renewal of erythroid progenitors. (A) Arginine-methylated 
proteins were immunoprecipitated and stained with two anti–methyl-
arginine antibodies (E76 and ASYM24) from cell lysates taken at 12-h 
intervals during differentiation of I/11 cells. The size of specific proteins 
is indicated in kilodaltons. X and Y represent uncharacterized proteins 
detected by ASYM24 at all stages of differentiation. The bottom panels 
represent whole cell extract probed for total levels of PRMT1 and ERK 
(loading control). (B) During differentiation of I/11 cells in the presence 
of Epo and in the absence or presence of MTA (10 and 25 mM), 
hemoglobin accumulation was quantified at days 2–4. Hemoglobin 
per cell volume is measured in arbitrary units. Values represent 
mean   SD of three measurements. (C) I/11 cells were seeded in 
differentiation medium in the presence of Epo (top) or Epo plus SCF 
(bottom), in the absence (left) or presence (right) of the methyl-
transferase inhibitor MTA (25 mM). At day 3 (Epo) or day 8 (Epo/SCF), 
cell morphology was analyzed in cytospins stained for hemoglobin 
(hemoglobinized cells stain orange/brown) and histological dyes. In 
the presence of MTA, cells retained a blast morphology and failed to 
accumulate hemoglobin.182 The Journal of Cell Biology | Volume 164, Number 2, 2004
did not show any alterations in erythroid differentiation (un-
published data). Thus, erythroid differentiation requires more
than a (p27
Kip-mediated) cell cycle arrest. In contrast to other
cells, erythroid differentiation requires three to four cell divi-
sions without size control to mature into erythrocytes. We
cannot conclude at present whether the newly identified
FoxO3a target BTG1 contributes to differentiation related
phenotypic changes like an altered cytoskeleton organization,
cell cycle arrest, chromatin condensation, and enucleation, or
whether it directly contributes to the early control of the bal-
ance between renewal and differentiation. However, the fact
that BTG1 controls protein methylation in erythroid differ-
entiation, and that this may contribute to control of renewal
versus differentiation, identifies a novel FoxO3a-dependent
mechanism that may regulate many aspects of the differentia-
tion process. The importance of BTG function is underscored
by the fact that the homologous family member BTG2 is sim-
ilarly suppressed by SCF and induced during differentiation
(Kolbus et al., 2003), although via a distinct mechanism. This
complementary regulation underscores the biological impor-
tance of BTG activation but precludes conclusive experiments
on the requirement for BTG1 by underexpression.
The role of BTG1 in protein methylation 
and differentiation
Screening of a cDNA array enriched for hematopoietic tran-
scripts identified BTG1 as a major FoxO3a target. Others
also reported BTG1 to be a potential Forkhead target (Ra-
maswamy et al., 2002), but so far, its role and regulation
were not studied in detail.
Activation of FoxO3a in expanding erythroblasts induced a
greater than twofold up-regulation of BTG1 within 2 h, indi-
cating a rapid induction. A more pronounced up-regulation is
detected during differentiation. However, FoxO3a(A3):ER
protein can only be expressed at low levels in expanding cells,
resulting in FoxO3a(A3):ER concentrations at best similar to
endogenous levels. In contrast, FoxO3a levels rise consider-
ably during differentiation. This difference on FoxO3a ex-
pression may explain the difference in BTG1 expression in
these experimental conditions. Expression of BTG1 is not
solely regulated by FoxO3a, we also reported BTG1 to be reg-
ulated by glucocorticoids (Kolbus et al., 2003), and it was
shown to be a putative vitaminD3 target (Savli et al., 2002).
Moreover, preliminary data suggest that CREB and FoxO3a
have to cooperate in BTG1 induction (unpublished data).
Thus, regulation of BTG1 may be complex, suggesting an im-
portant role in cell fate determination.
The BTG1 protein lacks enzymatic activity but contains
several protein interaction domains (Fig. 6 A), suggesting a
function as an adaptor molecule for enzymes and their targets
or as a regulatory cofactor. BTG1 has been shown to interact
with PRMT1 via its BoxC domain (Lin et al., 1996; Berthet
et al., 2002), resulting in positive regulation of PRMT1 ac-
tivity. Thus, BTG1 may direct the associated methyl trans-
ferase activity toward substrates binding to its NH2-terminal
domains (e.g., HOXB9 and the carbon catabolite repressor
[CCR4]–associated factor 1, CAF1; Bogdan et al., 1998;
Rouault et al., 1998; Prevot et al., 2000, 2001). Although ex-
pression of BTG1 in mouse bone marrow cells fully blocked
expansion of erythroid progenitors, deletion of the PRMT1-
associated BoxC domain largely abolished this negative ef-
fect, indicating that recruitment of PRMT1 is essential to the
function of BTG1 in erythroid differentiation. Erythroid
progenitors may be more sensitive to this function of BTG1
because BTG1 expression only marginally affected myeloid
colony formation induced by GM-CSF. Erythroid differenti-
ation seemed to require arginine methylation because its in-
hibition by MTA completely blocked terminal erythroid dif-
ferentiation without affecting the proliferation of immature
erythroblasts. Despite the fact that MTA inhibits other
S-adenosyl-L-methionine–dependent methyl transferases, we
can still conclude that methylation is required for terminal
differentiation and not for renewal of erythroblasts. Similarly,
global inhibitors of methylation also inhibited differentiation
in the PC12 cell line (Cimato et al., 2002) and PC12 cells
loaded with a penetratin–BTG1/BoxC fusion peptide failed
to differentiate, suggesting that neuronal differentiation in-
volves PRMT1 regulation by BTG1 (Berthet et al., 2002).
Overexpression of BTG1 inhibited myoblast proliferation
and induced differentiation (Rodier et al., 2001). BTG2, the
closest homologue of BTG1 was shown to be up-regulated in
neuronal differentiation (Bradbury et al., 1991; Corrente et
al., 2002) and to play a role in germ cell and muscle cell dif-
ferentiation (for review see Tirone, 2001).
It has become increasingly clear that arginine methylation
functions as a molecular switch, promoting or preventing
specific protein–protein interactions (for review see McBride
and Silver, 2001). PRMT1 contributes to 90% of the total
cellular arginine methyl transferase activity (Tang et al.,
2000), and mice lacking PRMT1 die at day 6.5 of develop-
ment, just before gastrulation occurs (Pawlak et al., 2000).
We showed that increased BTG1 expression after induction
of differentiation is accompanied by arginine methylation of
multiple proteins, ranging from 37 to 100 kD. The p100 de-
tected by 7E6 is detectable at 36 h, maximal at 48 h, and not
detected at later time points, although expression of BTG1
and PRMT1 persist. Possibly, its expression is only transient,
or the BTG1–PRMT1 complex is directed to other sub-
strates in the course of the differentiation program. PRMT1
was reported to induce methylation of STAT1, but STAT1,
STAT3, or STAT5 antibodies did not recognize the 100-kD
proteins. So far, we do not know the targets of PMRT1 in
erythroid differentiation. Interestingly, BTG1 interacts with
CAF1, and the CCR4–CAF1 complex is involved in hetero-
chromatin formation, gene silencing, and negative regulation
of mRNA stability (Bogdan et al., 1998; Tucker et al., 2001).
In erythroid cells, both PRMT1 and CAF1 are expressed
throughout differentiation at constant levels (this paper and
unpublished data), leaving the possibility that BTG1-medi-
ated activation of PRMT1 and CAF1 contributes to epige-
netic gene regulation including condensation of the nucleus
and enucleation late in erythroid differentiation.
Materials and methods
Cells and reagents
COS, 3T3, and ecotropic Phoenix cells were cultured in DME (Life Tech-
nologies) supplemented with 10% FCS (Life Technologies); BA/F3 were
cultured in RPMI 1640 supplemented with 10% FCS and 10 ng/ml murine
IL-3. LY294002 was obtained from Qbiogene, 4OHT and MTA were ob-
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Expansion and differentiation of erythroid progenitors
The erythroid cell line I/11 was cultured as described previously (von
Lindern et al., 2001). Cell numbers and cell size were determined using an
electronic cell counter (model CASY1; Schärfe-System). Cell morphology
was analyzed in cytospins stained with histological dyes and neutral benzi-
dine (Beug et al., 1982) using a microscope (model Bx4040; Olympus; 40 
objective, NA 0.65), CCD camera (model Dp50; Olympus), and Viewfinder
Lite (1.0) acquisition software. Images were cropped using Adobe photoshop
6.0. Hemoglobin was measured as described by Kowenz et al. (1987). In
short, 2–4   10
4 cells were washed in PBS, lysed in 20  l H2O, and frozen
until all samples were collected. 100  l of reagent mix (0.5 mg/ml o-phe-
nylenediamine [Sigma-Aldrich] and 0.03% H2O2 in 0.1 M citrate/phosphate
buffer, pH 5.0) was added to thawed samples, the reaction was stopped after
3 min with 20  l 8 N H2SO4, and the extinction of the reaction product was
read on an ELISA photometer at 492 nM, using the extinction at 690 nM as a
control. Extinction/cell number or extinction/cell volume was taken as a
measure for hemoglobinization. Apoptosis was determined using the TUNEL
assay according to the manufacturer’s protocol (Roche).
Generation of stable FoxO3a(A3):ER or FoxO3a-RNAi–expressing 
I/11 clones
The FoxO3a(A3):ER construct (Dijkers et al., 2002) was cloned in the retro-
viral expression vector pBABE-puro. Four RNAi constructs were cloned in
pSuper-retro (provided by Anton Berns, Netherlands Cancer Institute, Am-
sterdam, Netherlands): FOXi1 AATGAAGGCACGGGCAAGAGCTCTT;
FOXi2 AACCAGACACTCCAAGACCTGCTT; FOXi3 AGTGACTTGGAC-
CTGGACATGTT; and FOXi4 AGCCAGCTCGGCCATGGTGAT. These
constructs were transiently expressed in Phoenix cells, together with the
FoxO3a(A3):ER construct. Only the FOXi2 sequence suppressed FoxO3a
expression and was used for stable expression in I/11 cells. To obtain sta-
ble expression, 0.5   10
6 ecotropic Phoenix cells, seeded in 60-mm
dishes, were transfected with 16  g of plasmid DNA using calcium phos-
phate coprecipitation. 40 h after transfection, cells were treated with 10
 g/ml mitomycinC (Kyowa Hakko Kogyo) for 1 h and washed three times
with PBS, twice with an interval of  4 h. I/11 cells (0.5   10
6/ml) were
added and cocultured for 24 h in StemPro-34™
 plus factors. I/11 cells
were removed and grown in 2  g/ml puromycin containing (Sigma-
Aldrich) semisolid medium (Methocel-containing StemPro-34™ [Invitro-
gen], supplemented with factors). After 7 d, well-separated colonies were
picked, expanded, and analyzed for FoxO3a(A3):ER expression.
Western blotting and antibodies
I/11 cells were growth factor deprived for 4 h in plain IMDM (Life Technol-
ogies) and stimulated at 37 C with 100 ng/ml SCF or 5 U/ml Epo. Reac-
tions were stopped by the addition of ice-cold PBS. Cell lysis, immunopre-
cipitation, SDS-PAGE, and Western blotting were performed as described
previously (van Dijk et al., 2000). Antibodies used in this study were as
follows:   -HA (F-7; Santa Cruz Biotechnology, Inc.),  -FoxO4a (N-19;
Santa Cruz Biotechnology, Inc.),  -FoxO1a (Cell Signaling Technology),
 -FoxO3a (Upstate Biotechnology),  -phospho–FoxO3a (S-253; Upstate
Biotechnology),  -p27
Kip1 (BD Biosciences),  -ERK1/2 (K-23; Santa Cruz
Biotechnology, Inc.),  -STAT3 (C-20; Santa Cruz Biotechnology, Inc.),
 -mono- and dimethylarginine (7E6; Abcam),  -dimethylarginine (ASYM24;
Upstate Biotechnology), and  -PRMT1 (a gift from J.P. Rouault, Hôpital
Edouard Herriot, Lyon, France).
RNA isolation and real-time quantitative PCR
After 2-h stimulation (50 nM 4OHT, 5 U/ml Epo, and 100 ng/ml SCF), cells
were lysed, nuclei were removed, and RNA was isolated as described in
Kolbus et al. (2003). 1  g of total RNA was used to synthesize cDNA ex-
actly as described by Kolbus et al. (2003). The cDNA was diluted 1:10 to
1:200 before PCR amplification. The primer sequences used for the ampli-
fication of mBTG1 were as follows: forward, 5 -TGC AGG AGC TGC TGG
CAG-3 , and reverse, 5 -TGC TAC CTC CTG CTG GTG A-3 ; murine ribo-
nuclease inhibitor, forward, 5 -TCC AGT GTG AGC AGC TGA G-3 , and
reverse, 5 -TGC AGG CAC TGA AGC ACC A-3 . The real-time PCR assay
involves TaqMan technology (model 7700 or 7900 sequence detector; PE
Corp.). The reactions were performed as described by Kolbus et al. (2003).
The amplification program consisted of one cycle of 50 C with 2-min hold,
1 cycle of 95 C with 10-min hold, followed by 40 cycles of denaturation at
95 C for 15 s, annealing at 62 C for 30 s, and extension at 62 C for 30 s.
The CT values of RNase inhibitor were used to normalize the BTG1 values.
cDNA array hybridizations and analysis
Total RNA was used to hybridize a custom-made hematopoietic microarray
containing  9,000 cDNAs and enriched for erythroid and T cell–specific
cDNAs by subtracting cDNA of expanding I/11 cells and quiescent CD4  T
cells from cDNAs prepared from 3T3 fibroblasts and EpH4 epithelial cells. A
full description of the array and the array hybridization is available as sup-
plemental data. The quality of RNA was determined with a bioanalyzer
(model 2100; Agilent Technologies) according to the manufacturers instruc-
tions. For a single hybridization, 30  g total RNA was reverse transcribed
into cDNA using Cy5-UTP (CyDye; Amersham Biosciences), whereas con-
trol total RNA was labeled with Cy3-UTP. The microarrays were hybridized
and analyzed as described previously (Kolbus et al., 2003). The scanning
was performed using a Genepix 400A scanner (Axon Instruments, Inc.), and
the analysis was performed using the GenePix program.
Cloning of the BTG1 promoter and luciferase reporter assays
The mBTG1 cDNA clone L16846 was aligned to the mouse BTG1 genomic
sequence (CELERA) and the human BAC clone AC025164. The  1033/
 82 BTG1 promoter fragment was cloned into the pGL3-Basic vector
(Promega) after expansion by PCR using a 5  oligo (5 -GTG GTG TGT ATT
GCA TCT GAT GAC C-3 ), a 3  oligo (5 -CAC ATC GCT CGG ACC TCC
CCA GCC-3 ), and the Expand High Fidelity PCR system (Roche). The
 314/ 82 and the  67/ 82 promoter fragments were obtained using the
internal NheI and SmaI sites, respectively. The DBE1 was mutated using
the Quickchange site-directed mutagenesis kit (Stratagene) according to the
manufacturer’s protocol with primer 5 -CGG GGG GTT TAT TTA AAT
ACA AGC AGA TTA CG-3  and its complementary sequence.
For reporter assays, COS cells were seeded at 2.5   10
5 cells/35-mm
well (Costar) and transfected with 4  g DNA by calcium phosphate copre-
cipitation. After 24 h, cells were washed with PBS and subsequently lysed
in 25 mM Tris-phosphate (pH 7.8, 15% glycerol, 1% Triton X-100, 1 mM
DTT, and 8 mM MgCl2). Luciferase activity was measured using the
Steady-Glo system (Promega). LacZ determination was used to correct for
transfection efficiency.
Online supplemental material
Table S1 is an excel file that contains the data of the microarray analysis. A
MIAME compliant description of the microarray, the samples, and the hy-
bridization and scanning procedures is given as a separate pdf file. Online
supplemental material is available at http://www.jcb.org/cgi/content/full/
jcb.200307056/DC1.
We want to thank Dr. I.P. Touw for many critical discussions regarding the
work presented. We thank Herbert Auer for his patient help with the array
analysis, Claudia Antonissen for excellent technical assistance preparing
colony assays, and Dr. J.P. Rouault for his gift of anti-PRMT1 and for his
advice on experiments concerning BTG1.
This work was supported by grants from the Dutch Cancer Society (EUR
2000-2230), the European Union (HPRN-CT-2000-00083), the Nether-
lands Organization for Scientific Research (NWO 901-08-338), and fel-
lowships of the Erasmus University Rotterdam to T.B. van Dijk and the
Dutch Academy of Arts and Sciences to M. von Lindern.
Submitted: 9 July 2003
Accepted: 4 December 2003
References
Bao, H., S.M. Jacobs-Helber, A.E. Lawson, K. Penta, A. Wickrema, and S.T. Saw-
yer. 1999. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and
STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but
are constitutively active in an EPO-independent, apoptosis-resistant sub-
clone (HCD57-SREI cells). Blood. 93:3757–3773.
Berthet, C., F. Guehenneux, V. Revol, C. Samarut, A. Lukaszewicz, C. Dehay, C.
Dumontet, J.P. Magaud, and J.P. Rouault. 2002. Interaction of PRMT1
with BTG/TOB proteins in cell signalling: molecular analysis and functional
aspects. Genes Cells. 7:29–39.
Beug, H., S. Palmieri, C. Freudenstein, H. Zentgraf, and T. Graf. 1982. Hor-
mone-dependent terminal differentiation in vitro of chicken erythroleuke-
mia cells transformed by ts mutants of avian erythroblastosis virus. Cell. 28:
907–919.
Bogdan, J.A., C. Adams-Burton, D.L. Pedicord, D.A. Sukovich, P.A. Benfield,
M.H. Corjay, J.K. Stoltenborg, and I.B. Dicker. 1998. Human carbon
catabolite repressor protein (CCR4)-associative factor 1: cloning, expression
and characterization of its interaction with the B-cell translocation protein
BTG1. Biochem. J. 336:471–481.
Bradbury, A., R. Possenti, E.M. Shooter, and F. Tirone. 1991. Molecular cloning of
PC3, a putatively secreted protein whose mRNA is induced by nerve growth184 The Journal of Cell Biology | Volume 164, Number 2, 2004
factor and depolarization. Proc. Natl. Acad. Sci. USA. 88:3353–3357.
Brazil, D.P., and B.A. Hemmings. 2001. Ten years of protein kinase B signalling: a
hard Akt to follow. Trends Biochem. Sci. 26:657–664.
Broudy, V.C. 1997. Stem cell factor and hematopoiesis. Blood. 90:1345–1364.
Brunet, A., A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson,
K.C. Arden, J. Blenis, and M.E. Greenberg. 1999. Akt promotes cell sur-
vival by phosphorylating and inhibiting a Forkhead transcription factor.
Cell. 96:857–868.
Castrillon, D.H., L. Miao, R. Kollipara, J.W. Horner, and R.A. DePinho. 2003.
Suppression of ovarian follicle activation in mice by the transcription factor
Foxo3a. Science. 301:215–218.
Cimato, T.R., J. Tang, Y. Xu, C. Guarnaccia, H.R. Herschman, S. Pongor, and
J.M. Aletta. 2002. Nerve growth factor-mediated increases in protein meth-
ylation occur predominantly at type I arginine methylation sites and involve
protein arginine methyltransferase 1. J. Neurosci. Res. 67:435–442.
Corrente, G., D. Guardavaccaro, and F. Tirone. 2002. PC3 potentiates NGF-
induced differentiation and protects neurons from apoptosis. Neuroreport.
13:417–422.
Datta, S.R., A. Brunet, and M.E. Greenberg. 1999. Cellular survival: a play in
three Akts. Genes Dev. 13:2905–2927.
Dijkers, P.F., R.H. Medema, J.W. Lammers, L. Koenderman, and P.J. Coffer.
2000a. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated
by the forkhead transcription factor FKHR-L1. Curr. Biol. 10:1201–1204.
Dijkers, P.F., R.H. Medema, C. Pals, L. Banerji, N.S. Thomas, E.W. Lam, B.M.
Burgering, J.A. Raaijmakers, J.W. Lammers, L. Koenderman, and P.J. Coffer.
2000b. Forkhead transcription factor FKHR-L1 modulates cytokine-depen-
dent transcriptional regulation of p27(KIP1). Mol. Cell. Biol. 20:9138–9148.
Dijkers, P.F., K.U. Birkenkamp, E.W. Lam, N.S. Thomas, J.W. Lammers, L.
Koenderman, and P.J. Coffer. 2002. FKHR-L1 can act as a critical effector
of cell death induced by cytokine withdrawal: protein kinase B–enhanced
cell survival through maintenance of mitochondrial integrity. J. Cell Biol.
156:531–542.
Dolznig, H., F. Boulme, K. Stangl, E.M. Deiner, W. Mikulits, H. Beug, and E.W.
Mullner. 2001. Establishment of normal, terminally differentiating mouse
erythroid progenitors: molecular characterization by cDNA arrays. FASEB J.
15:1442–1444.
Dolznig, H., B. Habermann, K. Stangl, E.M. Deiner, R. Moriggl, H. Beug, and
E.W. Mullner. 2002. Apoptosis protection by the epo target bcl-x(l) allows
factor-independent differentiation of primary erythroblasts. Curr. Biol. 12:
1076–1085.
Erkeland, S.J., M. Valkhof, C. Heijmans-Antonissen, R. Delwel, P.J. Valk, M.H.
Hermans, and I.P. Touw. 2003. The gene encoding the transcriptional regu-
lator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neu-
trophilic differentiation. Blood. 101:1111–1117.
Furuyama, T., T. Nakazawa, I. Nakano, and N. Mori. 2000. Identification of the
differential distribution patterns of mRNAs and consensus binding se-
quences for mouse DAF-16 homologues. Biochem. J. 349:629–634.
Haseyama, Y., K. Sawada, A. Oda, K. Koizumi, H. Takano, T. Tarumi, M.
Nishio, M. Handa, Y. Ikeda, and T. Koike. 1999. Phosphatidylinositol
3-kinase is involved in the protection of primary cultured human erythroid
precursor cells from apoptosis. Blood. 94:1568–1577.
Hofmann, J.F., M. Sykora, N. Redemann, and H. Beug. 2001. G1-Cdk activity is
required for both proliferation and viability of cytokine-dependent myeloid
and erythroid cells. Oncogene. 20:4198–4208.
Kashii, Y., M. Uchida, K. Kirito, M. Tanaka, K. Nishijima, M. Toshima, T. Ando,
K. Koizumi, T. Endoh, K. Sawada, et al. 2000. A member of Forkhead fam-
ily transcription factor, FKHRL1, is one of the downstream molecules of
phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin sig-
nal transduction. Blood. 96:941–949.
Klingmuller, U., H. Wu, J.G. Hsiao, A. Toker, B.C. Duckworth, L.C. Cantley,
and H.F. Lodish. 1997. Identification of a novel pathway important for pro-
liferation and differentiation of primary erythroid progenitors. Proc. Natl.
Acad. Sci. USA. 94:3016–3021.
Kolbus, A., M. Blazques-Domingo, S. Carotta, W. Bakker, S. Luedemann, M. von
Lindern, P. Steinlein, and H. Beug. 2003. Cooperative signaling between cyto-
kine receptors and the glucocorticoid receptor in expansion of erythroid pro-
genitors: molecular analysis by expression profiling. Blood. 102:3136–3146.
Kops, G.J., N.D. de Ruiter, A.M. De Vries-Smits, D.R. Powell, J.L. Bos, and B.M.
Burgering. 1999. Direct control of the Forkhead transcription factor AFX by
protein kinase B. Nature. 398:630–634.
Kops, G.J., R.H. Medema, J. Glassford, M.A. Essers, P.F. Dijkers, P.J. Coffer,
E.W. Lam, and B.M. Burgering. 2002. Control of cell cycle exit and entry
by protein kinase B-regulated forkhead transcription factors. Mol. Cell. Biol.
22:2025–2036.
Kowenz, E., A. Leutz, G. Doderlein, T. Graf, and H. Beug. 1987. ts-oncogene-
transformed erythroleukemic cells: a novel test system for purifying and
characterizing avian erythroid growth factors. In Modern Trends in Human
Leukemia VII. R. Neth, R.C. Gallo, M.F. Greaves, and H. Kabisch, editors.
Springer Verlag, Heidelberg. 199–209.
Lin, W.J., J.D. Gary, M.C. Yang, S. Clarke, and H.R. Herschman. 1996. The
mammalian immediate-early TIS21 protein and the leukemia-associated
BTG1 protein interact with a protein-arginine N-methyltransferase. J. Biol.
Chem. 271:15034–15044.
Mahmud, D.L., M. G-Amlak, D.K. Deb, L.C. Platanias, S. Uddin, and A. Wick-
rema. 2002. Phosphorylation of forkhead transcription factors by erythro-
poietin and stem cell factor prevents acetylation and their interaction with
coactivator p300 in erythroid progenitor cells. Oncogene. 21:1556–1562. 
McBride, A.E., and P.A. Silver. 2001. State of the arg: protein methylation at argi-
nine comes of age. Cell. 106:5–8.
Medema, R.H., G.J. Kops, J.L. Bos, and B.M. Burgering. 2000. AFX-like Fork-
head transcription factors mediate cell-cycle regulation by Ras and PKB
through p27kip1. Nature. 404:782–787.
Pawlak, M.R., C.A. Scherer, J. Chen, M.J. Roshon, and H.E. Ruley. 2000. Argi-
nine N-methyltransferase 1 is required for early postimplantation mouse de-
velopment, but cells deficient in the enzyme are viable. Mol. Cell. Biol. 20:
4859–4869.
Prevot, D., T. Voeltzel, A.M. Birot, A.P. Morel, M.C. Rostan, J.P. Magaud, and L.
Corbo. 2000. The leukemia-associated protein Btg1 and the p53-regulated
protein Btg2 interact with the homeoprotein Hoxb9 and enhance its tran-
scriptional activation. J. Biol. Chem. 275:147–153.
Prevot, D., A.P. Morel, T. Voeltzel, M.C. Rostan, R. Rimokh, J.P. Magaud, and L.
Corbo. 2001. Relationships of the antiproliferative proteins BTG1 and
BTG2 with CAF1, the human homolog of a component of the yeast CCR4
transcriptional complex: involvement in estrogen receptor alpha signaling
pathway. J. Biol. Chem. 276:9640–9648.
Ramaswamy, S., N. Nakamura, I. Sansal, L. Bergeron, and W.R. Sellers. 2002. A
novel mechanism of gene regulation and tumor suppression by the transcrip-
tion factor FKHR. Cancer Cell. 2:81–91.
Raught, B., and A.C. Gingras. 1999. eIF4E activity is regulated at multiple levels.
Int. J. Biochem. Cell Biol. 31:43–57.
Rodier, A., P. Rochard, C. Berthet, J.P. Rouault, F. Casas, L. Daury, M. Busson, J.P.
Magaud, C. Wrutniak-Cabello, and G. Cabello. 2001. Identification of func-
tional domains involved in BTG1 cell localization. Oncogene. 20:2691–2703.
Rouault, J.P., D. Prevot, C. Berthet, A.M. Birot, M. Billaud, J.P. Magaud, and L.
Corbo. 1998. Interaction of BTG1 and p53-regulated BTG2 gene products
with mCaf1, the murine homolog of a component of the yeast CCR4 tran-
scriptional regulatory complex. J. Biol. Chem. 273:22563–22569.
Savli, H., Y. Aalto, B. Nagy, S. Knuutila, and S. Pakkala. 2002. Gene expression
analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: a
cDNA array study. Br. J. Haematol. 118:1065–1070.
Tang, E.D., G. Nunez, F.G. Barr, and K.L. Guan. 1999. Negative regulation of the
forkhead transcription factor FKHR by Akt. J. Biol. Chem. 274:16741–16746.
Tang, J., P.N. Kao, and H.R. Herschman. 2000. Protein-arginine methyltrans-
ferase I, the predominant protein-arginine methyltransferase in cells, inter-
acts with and is regulated by interleukin enhancer-binding factor 3. J. Biol.
Chem. 275:19866–19876.
Tang, T.T., D. Dowbenko, A. Jackson, L. Toney, D.A. Lewin, A.L. Dent, and
L.A. Lasky. 2002. The forkhead transcription factor AFX activates apoptosis
by induction of the BCL-6 transcriptional repressor. J. Biol. Chem. 277:
14255–14265.
Tirone, F. 2001. The gene PC3(TIS21/BTG2), prototype member of the PC3/
BTG/TOB family: regulator in control of cell growth, differentiation, and
DNA repair? J. Cell. Physiol. 187:155–165.
Tucker, M., M.A. Valencia-Sanchez, R.R. Staples, J. Chen, C.L. Denis, and R.
Parker. 2001. The transcription factor associated Ccr4 and Caf1 proteins are
components of the major cytoplasmic mRNA deadenylase in Saccharomyces
cerevisiae. Cell. 104:377–386.
van Dijk, T.B., E. van Den Akker, M.P. Amelsvoort, H. Mano, B. Lowenberg, and
M. von Lindern. 2000. Stem cell factor induces phosphatidylinositol 3 -
kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic
cells. Blood. 96:3406–3413.
von Lindern, M., E.M. Deiner, H. Dolznig, M. Parren-Van Amelsvoort, M.J.
Hayman, E.W. Mullner, and H. Beug. 2001. Leukemic transformation of
normal murine erythroid progenitors: v- and c-ErbB act through signaling
pathways activated by the EpoR and c-Kit in stress erythropoiesis. Oncogene.
20:3651–3664.